Colchicine for Stroke Prevention (CHANCE-3 Trial)
📍 Study Type: Randomized, placebo-controlled trial
🏥 Setting: 244 hospitals in China
👥 Participants: 8,343 patients (age ≥40) with minor/moderate ischemic stroke or TIA & hs-CRP ≥2 mg/L
Intervention vs. Control
💊 Colchicine Group (n=4,176)
• 0.5 mg twice daily (Days 1-3) → 0.5 mg daily (Days 4-90)
💊 Placebo Group (n=4,167)
• Identical dosing schedule
Key Outcomes (90 Days)
✅ Primary Efficacy: Any stroke
• Colchicine: 6.3% (264 patients)
• Placebo: 6.5% (270 patients)
📉 No significant difference (HR 0.98, P=0.79)
⚠️ Primary Safety: Serious adverse events
• Colchicine: 2.2%
• Placebo: 2.1%
🔹 No significant difference (P=0.83)
Conclusion
📌 Colchicine did not reduce stroke risk within 90 days in high-risk patients.
📌 Safety profile was similar to placebo.